[Bone marrow graft in hereditary diseases].

Abstract

Since 1968, bone marrow transplantation became the first line therapy for selected metabolic and immunological hereditary disorders. Actually, advances in the supportive care in bone marrow transplantation and a better knowledge of the immunology of BMT complications has been associated with a better disease correction and an increase in long term survival. New approaches are under investigation and include: hematopoietic growth factors, enzymatic replacement and gene therapy. However at the present time BMT is still the only curative treatment for selected hereditary disorders.

• Authors: W Bujan, A Ferster, C Devalck, E Vamos, F Mascart, R Denis, N Azzi, P Vergauwen, E Sariban
• Journal: Revue medicale de Bruxelles (Rev Med Brux) Vol. 13 Issue 6 Pg. 207-11 (Jun 1992) ISSN: 0035-3639 [Print] Belgium
• Vernacular Title: La greffe de moelle dans les maladies héréditaires.
• PMID: 1631420 (Publication Type: English Abstract, Journal Article)

Chemical References

• Growth Substances

Topics

• Bone Marrow Transplantation
• Chediak-Higashi Syndrome (therapy)
• Genetic Diseases, Inborn (classification, therapy)
• Growth Substances (therapeutic use)
• Humans
• Metabolism, Inborn Errors (therapy)
• Wiskott-Aldrich Syndrome (therapy)